{"brief_title": "A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)", "brief_summary": "This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.", "detailed_description": "A phase IIIB randomized, open-label, multicenter, parallel-arm study to evaluate the short-term safety and tolerability of the abacavir/lamivudine fixed-dose combination tablet administered once-daily or the separate abacavir and lamivudine tablets administered twice-daily, as part of a three or four-drug regimen, in antiretroviral naive HIV-1 infected subjects.", "condition": ["HIV Infection"], "intervention_type": ["Drug"], "intervention_name": ["Abacavir/Lamivudine"], "criteria": "Inclusion Criteria: - Have HIV-1 infection. - Had not received any prior HIV treatment for more than 14 days. - At least 1000 copies of HIV-1 RNA. - Willing to provide signed informed consent. Exclusion Criteria: - Enrolled in other investigational drug studies. - Female subjects who are pregnant or breastfeeding. - History of allergy or hypersensitivity to abacavir or lamivudine. - Certain medical conditions that would make subjects ineligible.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "naive", "mesh_term": ["HIV Infections", "Abacavir", "Lamivudine"], "id": "NCT00094367"}